Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Abstract Text:

Caroline M Forrest,Gillian M Mackay,Nicholas Stoy,Trevor W Stone,L Gail Darlington,

AIM: Since melatonin is antioxidant and has some anti-inflammatory actions, we have tested it as adjunctive treatment in patients with rheumatoid arthritis, to determine whether it can improve patients' symptoms. METHODS: A total of 75 patients were allocated randomly to receive melatonin 10 mg at night in addition to ongoing medication, or a placebo of identical appearance. Monthly blood samples were taken and disease severity assessed over 6 months, plasma being analysed for inflammatory indicators [C-reactive protein, erythrocyte sedimentation rate (ESR), neopterin], proinflammatory cytokines [interleukin (IL)-1beta, IL-6, tumour necrosis factor (TNF)-alpha], lipid peroxidation products and the kynurenine pathway metabolites of tryptophan. RESULTS: An increase of ESR (two-way anova F((1,127)) = 5.24, P = 0.024) and neopterin concentrations (F((1,136)) = 4.64, P = 0.033) was observed in treated patients compared with controls, reflected also in a significant trend for both to decline in placebo-treated patients (P = 0.022), but not the melatonin-treated group. Peroxidation products showed a significant trend to decrease in placebo- but not melatonin-treated patients. These results suggest a proinflammatory action, but there were no significant effects of melatonin treatment on clinical assessments of patient symptoms or the concentrations of three proinflammatory cytokines, IL-1beta, IL-6 and TNF-alpha. Melatonin significantly increased plasma kynurenine concentrations (F((1,124)) = 4.24, P = 0.041), again suggesting proinflammatory activity. CONCLUSION: A daily dose of 10 mg melatonin shows a slowly developing antioxidant profile in patients with arthritis and increases the concentrations of some inflammatory indicators, but these effects are not associated with any change of proinflammatory cytokine concentrations or clinical symptoms.

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Publishing Authors By Initials

CM Forrest,GM Mackay,N Stoy,TW Stone,LG Darlington,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of clinical pharmacology

VOLUME: 64

Page Numbers: 517-26

Journal Abbreviation:

ISSN: 0306-5251

DAY: 15

MONTH: 05

YEAR: 2007

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503323

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.

AFFILIATION: Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin Related Publications

• Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole.
• Alterations in xenobiotic metabolism in the long-lived Little mice.
• Blood and speech.
• Comparative field performance over 3 years and two sites of transgenic wheat lines expressing HMW subunit transgenes.
• Cytosolic glucocorticoid receptor expression in the rat vestibular nucleus and hippocampus following unilateral vestibular deafferentation.
• Effects of intra-vestibular nucleus injection of the group I metabotropic glutamate receptor antagonist AIDA on vestibular compensation in guinea pigs.
• Genetic particles.
• Glutamate receptor subunits expression in memory-associated brain structures: Regional variations and effects of aging.
• Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.
• Lymphoid neogenesis and immune infiltration in aged liver.
• MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
• Medical history, sexual, and maturational factors and prostate cancer risk.
• Oral tumors.
• Osteonecrosis at multiple sites in a patient with systemic lupus erythematosus.
• Overview of research on health-related quality of life in patients with chronic liver disease.
• Quantitative changes in gene expression of glutamate receptor subunits/subtypes in the vestibular nucleus, inferior olive and flocculus before and following unilateral labyrinthectomy in the rat: real-time quantitative PCR method.
• Reproductive versatility in Rubus; raspberry-blackberry hybrids; on an integrated species difference.
• The changing face of insulin receptors.
• The contribution of nitric oxide to vestibular compensation: are there species differences?
• The effect of delta 9-tetrahydrocannabinol on the extinction of an adverse associative memory.
• The geographical distribution of cold-blooded vertebrates.
• The geographical distribution of cold-blooded vertebrates.
• The plasmagene theory of the origin of cancer.
• The transcription factor HNF1 acts with C/EBP alpha to synergistically activate the human albumin promoter through a novel domain.
• Threat of disease in tropical crops.
• Transcriptional profiling of bipotential embryonic liver cells to identify liver progenitor cell surface markers.
• Tryptophan, adenosine, neurodegeneration and neuroprotection.